Rare diseases
Investigational molecules
Locations
Back to Hungary26 clinical trials in Mosonmagyaróvár, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.
Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation
HungaryStudy on Inclisiran for Preventing Heart Disease in High-Risk Patients
HungaryA study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups
HungaryStudy of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups
HungaryStudy of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups
HungaryStudy on the Effects of Itepekimab in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
HungaryStudy on Long-Term Safety of Depemokimab for Adults and Adolescents with Severe Eosinophilic Asthma
HungaryStudy of XXB750 and Drug Combination for Patients with Heart Failure
HungaryStudy on the Effectiveness and Safety of Fluticasone Propionate and Salbutamol Sulfate for Patients with Asthma
HungaryHungaryStudy on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)
HungaryStudy on the Long-term Effects of Dupilumab in Preventing Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma
HungaryThe busiest research cities in the country
What the registry says about research in the country
Multiple innovative trials focusing on moderate to severe asthma management, testing new therapeutic approaches including lunsekimig, dupilumab, and amlitelimab. Research aims to prevent lung function decline and reduce exacerbations.
Studies particularly emphasize long-term safety and efficacy in patients with eosinophilic phenotype.
Clinical research focusing on Chronic Obstructive Pulmonary Disease (COPD), evaluating new treatments like itepekimab and investigating improved delivery systems for existing medications.
Emphasis on moderate to severe COPD patients and former smokers.
Comprehensive studies in heart failure and atrial fibrillation, testing breakthrough treatments including ponsegromab, milvexian, and vericiguat for improved patient outcomes.
Focus on reducing major adverse cardiovascular events and improving quality of life.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
